Abstract:Abstract Disclosure: M.J. McPhaul: Consulting Fee; Self; Quest Diagnostics. J.Z. Louie: Employee; Self; Quest Diagnostics. D. Shiffman: Consulting Fee; Self; Quest Diagnostics. F. Bril: None. Nonalcoholic fatty liver disease (NAFLD) has been renamed metabolic dysfunction-associated steatotic liver disease (MASLD), and its definition has also been updated to include the presence of at least one cardiometabolic (CM) risk factor. The aim of this study was to assess the demographic and biochemical characteristics of patients with NAFLD, who do not meet criteria for MASLD, and to assess the effect of cumulative number of CM risk factors on liver disease severity. Methods: The study population included 33,674 participants in the 2020 annual wellness program of a nation-wide employer that included laboratory tests and anthropometric measurements, after excluding those with incomplete data and BMI <18.5 kg/m2. Hepatic steatosis was defined as intact insulin (II)*ALT ≥290 (Bril et al, JCEM 2021). CM risk factors were defined according to MASLD definition. Differences between groups were assessed using t-tests or Chi-square tests. The association between number of CM risk factors and hepatic steatosis was assessed by a trend test. Association with II, AST, and ALT was assessed by linear regression models. Results: A total of 7,059 (27%) participants had hepatic steatosis. However, 61 (1%) of these participants did not have any CM risk factors, and thus had NAFLD, but not MASLD. Compared with participants with no steatosis, they were younger (-8 [95% CI: -10 to -5] years), had a lower fraction of women (54 vs. 67%, p=0.04), higher fraction of Hispanic patients (28 vs. 13%, p=0.0007). Despite absence of CM risk factors, 39% were insulin resistant (II>10.5 uIU/mL). This group of patients with no CM risk factors had plasma AST and ALT levels that were higher than MASLD patients (p <0.002). Among patients with hepatic steatosis and only 1 CM risk factor, the most common CM risk factors were overweight, obesity, or increased waist circumference. Less than 15% had any glucose, lipid, or BP abnormality. Higher number of CM risk factors was associated with a higher prevalence of hepatic steatosis (p<0.0001). Among patients with MASLD, higher number of CM risk factors was associated with higher levels of II (p<0.0001), but not with higher AST or ALT (both p>0.15). Conclusion: Changes in NAFLD definition resulted in a new subgroup of patients that were previously defined as NAFLD, but do not have MASLD. Our results showed that this group of patients are likely to have insulin resistance and may be at risk of liver fibrosis, despite their lack of CM risk factors. Presentation: 6/2/2024

From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research

From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus

Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology

MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease

Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond

Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration

From NAFLD to MASLD: when Metabolic Comorbidity Matters.

Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: results from a single-center biopsy study

From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology

New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice

[NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures]

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity

Transitioning from NAFLD to MAFLD and MASLD: Consistent Prevalence and Risk Factors in a Chinese Cohort

MASLD: What We Have Learned and Where We Need to Go-A Call to Action

[Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases]

Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities

Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population

Clinical significance of renaming nonalcoholic fatty liver disease

7042 From NAFLD to MASLD: Assessing the Impact of Changing the Definition of Fatty Liver Disease

From Pathogenesis to Current Therapeutic Options

Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice